Category | Variables | 68 patients (%) |
---|---|---|
Age, years | Median (range) | 71 (43–84) |
Sex | Female | 13 (19.1) |
Male | 55 (80.8) | |
ECOG PS | 0 | 37 (54.4) |
1 | 27 (39.7) | |
2 | 4 (5.8) | |
Charlson comorbidity index | 0 | 25 (36.7) |
1 | 23 (33.8) | |
2 | 15 (22.0) | |
3–4 | 5 (7.3) | |
Smoking status | Never | 9 (13.2) |
Current | 27 (39.7) | |
Former | 32 (47.0) | |
Brinkman index | Median (range) | 800 (0–1900) |
FEV1 (L) | Median (range) | 2.18 (1.12–3.67) |
FEV1 (% of predicted) | Median (range) | 88.0 (36.4–125.4) |
FEV1/FVC (%) | Median (range) | 71.6 (32.1–89.0) |
Interstitial lung disease | No | 65 (95.5) |
Yes | 3 (4.4) | |
Diabetes mellitus | No | 56 (82.3) |
Yes | 12 (17.6) | |
COPD | No | 48 (70.5) |
Yes | 20 (29.4) | |
Pathology | Adenocarcinoma | 32 (47.0) |
Squamous cell carcinoma | 27(39.7) | |
Others | 9 (13.2) | |
PD-L1 tumour proportion score |  < 1% | 11 (16.2) |
 ≥ 1% | 31 (45.6) | |
Unknown | 26 (38.2) | |
Stage (UICC 8th) | IIA-IIB | 8 (11.7) |
IIIA | 23 (33.8) | |
IIIB | 31 (45.5) | |
IIIC-IVA | 6 (8.8) | |
Chemotherapy | No | 18 (26.4) |
Yes | 50 (73.5) | |
 - Cisplatin/vinorelbine | 24 | |
 - Carboplatin/paclitaxel or nab-paclitaxel | 20 | |
 - Others | 6 | |
Total prescribed dose | 60 (Gy) | 56 (83.3) |
66 (Gy) | 10 (14.7) | |
Others | 2 (2.9) | |
PTV (cc) | Median (range) | 305.5 (77.6–958.9) |
Radiation dose parameters | Dose coverage 90% of CTV (Gy) | 60.9 (58.8–68.6) |
Dose coverage 90% of PTV (Gy) | 58.9 (55.5–66.0) | |
Median (range) | Lung V5 Gy (%) | 56.2 (27.9–84.0) |
Lung V20 Gy (%) | 23.6 (11.1–35.1) |